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Abstract
MicroRNAs (miRNAs) are a class of short RNAs that regulate gene expression through either translational repression or
mRNA cleavage. miRNA-181a (miR-181a), one of the many miRNAs conserved among vertebrates, is differentially expressed
in a variety of leukemia. However, its function in leukemia, particularly chronic myelogenous leukemia (CML), is poorly
understood. Here we have reported the identification of miR-181a targets by combining TargetScan software prediction
and expression profiling through overexpression of miR-181a mimic in leukemic K562 cells. Four overlapping genes were
found to be the likely targets of miR-181a. Among the four genes, RalA is a downstream molecule of bcr-abl fusion protein
in ras signaling pathway. However, its role in CML remains elusive. Luciferase reporter and Western blot assays confirmed
that RalA is a direct target of miR-181a. overexpression of miR-181a effectively suppresses cell growth and induces G2-phase
arrest and apoptosis partially by targeting RalA in leukemic K562 cells. Using the KEGG database combined with recent
publications, downstream signaling pathway of RalA was graphed by cytoscape software. Therefore, our study is the first to
report that RalA is directly regulated by miR-181a and plays an important role in CML. The approach of computational
prediction combined with expression profiling might be valuable for the identification of miRNA targets in animal.
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Introduction
MicroRNAs (miRNAs) are a new class of endogenous noncoding
small RNA molecules that have been shown to be important
regulatorsofgene expressionincells.miRNAspost-transcriptionally
regulate gene expression by either cleavage or repression of mRNA
through binding to the 39-untranslated region (39-UTR) of the
target genes [1],[2]. Bioinformatics prediction indicates that 30% of
all the genes are regulated by miRNAs [3]. Currently, more than
1000 miRNAs have been identified in humans [4]. They are known
to be involved in a variety of functions in development, cell
proliferation, apoptosis, differentiation, and tumorigenesis [1],[2].
Thus, miRNA functional identification has become one of the most
attractive research fields in biomedicine. Unfortunately, most of
these miRNAs have unknown functions [5]. One major obstacle is
to identify the targets regulated by miRNAs. Since there is partial
complementarily between miRNAs and their targets in animal cells,
the identification of specific target genes for a given miRNA is still a
big challenge in our understanding of the miRNA functions.
Computation-based approaches for miRNA gene identification and
miRNA target prediction are considered as indispensable in
miRNA research. Several computational approaches have been
developed for the prediction of miRNA targets.
Computational algorithms based on the factors, such as free
binding energy or sequence conservation, have been used to
predict miRNA targets. The prediction of miRNA targets has
been based on putative binding sites within the 39-UTRs of the
transcripts [6]. The efficacy of the computational approaches to
locate and rank the potential binding sites is supported by the
relatively high degree of miRNA complementarity to the
experimentally determined binding sites. Based on such predic-
tions, up to one-third of all mammalian mRNAs appear to be
under miRNA regulation.
Despite the subsequent identification of hundreds of miRNAs in
a variety of species, only a handful of targets have been confirmed
experimentally [7]. Owing to the imperfect complementarity
between any given miRNA and its targets, computational
predictions are often hindered by false-positives. Therefore,
effective experimental techniques to validate the predictions are
crucial for the testing and fine-tuning of computational algorithms
[8],[9].
It was previously presumed that most miRNAs regulate the
target gene expression via mRNA degradation in plants [10],
whereas in animals, miRNAs are considered to suppress the target
gene translation [2]. However, recent studies have convincingly
demonstrated that the levels of animal mRNAs are also altered if
the target-binding sites have perfect sequence complementarity to
the miRNA [11]. Furthermore, miR-16 has been shown to
mediate mRNA degradation, even if the binding site has only a
partial sequence match [12]. Currently, mounting evidence has
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32834shown that animal miRNAs can reduce the mRNA levels via
mRNA degradation, and that extensive complementarity is not
always required [13],[14]. These findings indicate that it is more
convenient for miRNA target validation to monitor mRNA
changes using a high-throughput experimental approach when
compared with changes in protein expression.
Overexpression of miRNA in cells has been reported to lead to
the downregulation of a large number of transcripts, as revealed by
the microarrays [9],[15],[16]. A significant enrichment of miRNA
complementary sequences in these downregulated genes has been
observed, implying that it might be possible to use microarrays to
simultaneously identify a large number of miRNA targets.
miRNA-181a (miR-181), one of the many miRNAs conserved
among the vertebrates, is preferentially expressed in the B
lymphocytes of bone marrow, and its ectopic expression in
hematopoietic stem/progenitor cells modulates the blood cell
development [17]. Recent studies have shown that miR-181a is
differentially expressed in a variety of leukemia [18],[19],[20].
However, little is known about the role of miR-181a in chronic
myeloid leukemia (CML).
In our previous research, we found that the expression of miR-
181a is very low such that it cannot be detected by quantitative
real-time PCR in K562 cells, indicating that downregulation of
miR-180a might play an important role in leukemogenesis. To
elucidate the function of miR-181a in CML, it is important to
identify its target genes. In the present study, we have combined
computational prediction and expression profiling methods to
systematically identify the miR-181a targets following overexpres-
sion of miR-181a mimic. Our data show that RalA is a direct
target gene of miR-181a and associated with cell proliferation, G2-
phase arrest and apoptosis in CML.
Results
miR-181a target prediction
TargetScan, the first method employed for human miRNA
target prediction using mouse, rat, and fish genomes for
conservation analysis [7], was used to predict miR-181a targets.
A total of 691 genes were predicted to be putative targets of miR-
181a. These genes, including tumor suppressor genes and
oncogenes, are involved in various aspects of functions implicated
in cancer, including control of cell proliferation, apoptosis, signal
transduction, transcription regulation, immunity and defense
(Table S1).
miR-181a transfection microarray
miR-181a duplex molecule RNA (mimic) was transfected into
the K562 cells. Gene expression profiling was conducted 48 h
post-transfection. From the 20173 screened genes, 248 genes were
differentially expressed between control and miR-181a transfected
cells. Among them, 65 genes showed increased expression,
whereas 183 genes showed decreased expression compared to
the control. As miRNAs are known to cause degradation or
translational repression of target mRNAs, we focused on the genes
that are downregulated in miR-181a-transfected cells. The
majority of the downregulated genes were found to be involved
in the regulation of cell cycle and proliferation, DNA-binding and
transcription, metabolism, signal transduction, development, etc.
(Table S2.), suggesting that miR-181a may be involved in various
aspects of leukemia.
Characterization of the downregulated miR-181a targets
Four of the predicted targets were subsequently confirmed to be
downregulated by miR-181a in K562 cells. One of them, RalA, is
a v-ral simian leukemia viral oncogene homolog A (ras-related)
(Table 1) involved in tumorigenesis and cancer invasion [22],[23].
Thus we next wanted to experimentally validate whether RalA is a
direct target of miR-181a (Figure 1).
The RalA-39-UTR is a target for miR-181a
We first determined whether the 39-UTR of the RalA gene
contains functional miR-181a targeting sequence(s), and whether
direct interaction between the two takes place. To this end, we
constructed dual-luciferase reporter a pair of plasmids containing
two tandem miR-181a recognition sequences from the 39-UTR of
RalA mRNA and the mutated recognition sequences immediately
downstream of the luciferase gene (psi-CHECK-2-RalA-UTR and
psi-CHECK-2-RalA-mut-UTR reporter, respectively). Using
these plasmids, we performed dual-luciferase reporter assays. As
shown in Figure 2AB, transfection with miR-181a significantly
decreased the activity of psi-CHECK-2-RalA-UTR, but not psi-
CHECK-2-RalA-mut-UTR, reporter in the K562 cells. Taken
together, these data suggest that the RalA might be a direct target
of miR-181a in K562 cells.
miR-181a downregulates RalA mRNA and protein level
Next, we tested whether miR-180a can downregulates RalA
mRNA in K562 cells. The miRNA transfection in K562 cells was
efficient as the level of miR-181a was increased by 140-fold in
miR-181a transfected cells compared to scrambled RNA trans-
fected cells (Figure 3A). Subsequently, we evaluated the effects of
miR-181a on the expression of RalA protein and mRNA using
immunoblot and RT-real-time PCR analysis. As shown in Fig. 3B,
overexpression of miR-181a resulted in a moderate reduction in
the RalA mRNA levels and reduced RalA protein level. This
reduction if comparable to that mediated by transfection of RalA
siRNA in K562 cells (Figure 3C).
miR-181a suppresses cell growth partially by targeting
RalA
To determine whether miR-181a affects cell growth, we
transfected K562 cells with scrambled RNA, miR-181a or RalA
Table 1. Characterization of RalA gene.





5898 RalA 0.6862 0.0013 20.26 v-ral simian leukemia viral
oncogene homolog A (ras-
related)
p-value LogRatio was used as the criteria to estimate differences in the gene expression on array. The total context score was used to assess whether there was
significance in the predicted miR-181a targets in the downregulated genes.
doi:10.1371/journal.pone.0032834.t001
miR-181a Downregulates RalA
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32834Figure 1. Downregulated genes upon miR-181a overexpression. miR-181a targets were identified by combining TargetScan software
prediction and expression profiling. The four genes identified by both methods were considered as candidate targets of miR-181a in K562 cells.
doi:10.1371/journal.pone.0032834.g001
Figure 2. miR-181a-directed repression of Renilla luciferase reporter genes containing RalA-39-UTR segments. K562 cells were
cotransfected with scrambled RNA or miR-181a together with RalA-39-UTR or RalA-mut-39-UTR luciferase reporter in the presence of firefly luciferase
reporter plasmid as indicated. Renilla luciferase activity and firefly luciferase activity were measured by dual-luciferase reporter assay (Promega).
Renilla luciferase activity was normalized to firefly luciferase activity. The data represent the mean value of three independent experiments. (A)
overexpression of miR-181a significantly repressed Renilla luciferase activity in cells transfected with RalA-39-UTR, but not RalA-mut-39-UTR vector;
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RalA siRNA effectively inhibited cell viability in a time-dependent
manner. RalA siRNA seemed to have stronger effects, although
not statistically different, than miR-181a (no difference in statistics
was observed). These findings strongly suggest that miR-181a
suppressed cell growth at least partially by targeting RalA
(*p,0.01) (Figure 4AB).
miR-181a induces G2-phase arrest partially by
targeting RalA
To elucidate the influence of miR-181a on cell cycles, K562
cells transfected with above scramble, miR-181a or RalA siRNA
were subjected to cell cycle analysis. As shown in Figure 5,
overexpression of miR-181a resulted in an accumulation of cells in
G2/M. Interestingly, siRNA RalA produced almost identical
effects on cell cycles (Figure 5). These results suggest that miR-
181a-induced G2/M arrest is at least partially due to its targeting
of the RalA gene.
miR-181a promotes apoptosis partially by targeting RalA
Finally, we determined whether miR-181a is involved in apoptosis.
K562 cells transfected with scrambled, miR-181a or RalA siRNA
were stained with Annexin V and PI followed by flow cytometry. As
shown in Fig. 6, overexpression of miR-181a significantly decreased
apoptosis in these cells. The results demonstrated that miR-181a
induced cell apoptosis at least partially by targeting RalA.
Pathway of RalA
Using the KEGG database, combined with recent publication,
we analyzed genes in downstream of RalA signaling pathways,
including the Rac-family GTPase-activating protein RLIP (also
known as RLIP76 and ralA binding protein 1 (RALBP1)),
CDC42(cell division cycle 42), RAC1 (ras-related C3 botulinum
toxin substrate 1), RAC2, RAC3, the Y-box transcription factor
ZO-1-associated nucleic acidbinding protein (ZONAB, also
known as cold shock domain protein A (CSDA)), and two subunits
of the exocyst complex, SEC5 (also known as exocyst complex
component 2 (EXOC2)) and EXO84 (also known as EXOC8),
which are involved in regulating cell proliferation, apoptosis and
migration. The result was graphed using cytoscape to show the
interactions between RalA and its potential targets(Figure 7).
Discussion
Prediction of animal miRNA targets is very challenging owing
to the imperfect pairing of a given miRNA with its targets as well
Figure 3. miR-181a regulates RalA expression at the post-transcriptional level. K562 cells were transfected with scrambled RNA, miR-181a,
or RalA siRNA and harvested 48 h after transfection. Total RNA was isolated and analyzed for the expression of miR-181a (A), RalA mRNA (B) and RalA
protein (C) using qPCR and Western blot, respectively. *p,0.01, when compared with controls.
doi:10.1371/journal.pone.0032834.g003
miR-181a Downregulates RalA
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32834as the fact that the gene expression is in a tissue-specific and/or
time-specific manner [1]. This predictive may have a high false-
positive rate that may require experimental verification.
While mRNA microarray analysis following miRNA inhibition
or overexpression is a relatively simple and robust method for
target identification, this approach, as per definition, cannot
identify mRNAs subjected exclusively to the translational
repression. In other words, this method may produce a high
false-negative result. However, this disadvantage may not be as
severe as initially thought, as the recent data suggest that it is a
common mechanism for animal miRNAs to downregulate target
mRNA expression and that the majority of miRNA regulation can
be detected at the mRNA levels [16]. This allows to identify and
experimental validation of target genes using mRNA expression
profiling. Hence, we attempted to identify miRNA-181a target
genes using a combination of computational prediction and
expression profiling. As a result, we identified four candidate
targets of miR-181a.
Among them, RalA is found to play important roles in
tumorigenesis and cancer invasion [22],[23]. Our dual-luciferase
reporter and Western blot assays confirmed that RalA contains a
miR-181 binding site at its 39-UTR and is directly regulated by
miR-181a (Figure 2A, 3C). overexpression of miR-181a signifi-
cantly downregulated the RalA mRNA level (Figure 3B), Sug-
gesting that RalA is an authentic miR-181a target.
RalA and its isoform RalB are multifunctional GTPases
involved in the control of cell proliferation, oncogenic transfor-
mation, and membrane trafficking [22],[24]. Although RalA and
RalB share about 85% of their amino acid sequences, the
functions of the two isoforms are only partially overlapping. RalA
and RalB have antagonistic effects on cancer cell migration, but
possess overlapping functions in cell growth [25]. Lim et al.
Figure 4. miR-181a inhibits K562 cells growth partially by targeting RalA. K562 cells were transfected with scrambled RNA, miR-181a, or
RalA siRNA. Viability of the cells was assessed by MTT (A) and trypan blue exclusion assay (B) in triplicates. Both miR-181a and siRNA RalA effectively
inhibited cell viability in a time-dependent manner. *p,0.01, when compared with blank or Scramble controls.
doi:10.1371/journal.pone.0032834.g004
miR-181a Downregulates RalA
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pancreatic tumor tissue and that the RalA function is critical to
tumor initiation, whereas RalB function is more important for
tumor metastasis in the tested cell lines [26].
RalA, one of the Ral family small G proteins, has been
implicated in tumorigenesis, invasion, and metastasis of a variety
of solid tumors [22]. Thus, activation of RalA signaling appears to
be a critical step in the Ras-induced transformation and
tumorigenesis [23]. Wang et al. showed that RalA contributes to
liver malignant transformation and could be a potential tumor
marker in hepatocellular carcinoma (HCC) [27]. Shi et al.
reported that miR-181a and miR-181b function as tumor
suppressors by inducing cell growth inhibition apoptosis, and
repression of invasion in glioma cells [28].
CML results from the transformation of primitive hematopoi-
etic cells by the Bcr/Abl gene product. BCR-ABL regulates
activation of many mitogenic and pro-survival pathways, including
the PI 39K/AKT/mTOR pathway that controls various effectors.
Recent research showed that AMPK and/or AXL, overexpression
in Imatinib (IM)-resistant CML cell lines and patients, might be
novel target in treatment of refractory CML [29],[30]. In our
KEGG analysis, several important genes were shown downstream
to the RalA signaling pathways, including RALBP1, CDC42,
RAC1, RAC2, RAC3, ZONAB, and SEC5 and EXO84
(Figure 7), further supporting the notion that RalA function is
critical to tumor initiation.
Further research demonstrates that Bcr-Abl oncoprotein binds
directly to activators of the Ras signaling pathway and effector
Figure 5. miR-181a regulates cell cycles partially by targeting RalA. K562 cells were transfected with scrambled RNA, miR-181a, or RalA
siRNA and harvested 48 h post-transfection. The cells were stained with PI solution and analyzed using flow cytometry. Both miR-181a and RalA
siRNA significantly induced G2-phase arrest. *p,0.01, when compared with blank or SCR controls.
doi:10.1371/journal.pone.0032834.g005
miR-181a Downregulates RalA
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pathway, play a major role in Bcr-Abl-induced leukemogenesis
[31],[32],[33]. Therefore, RalA, as one small GTPase molecule of
the Ras network, might also play an important role in oncogenesis
of CML.
It has clearly been demonstrated that the most primitive stem
cells are refractory to all TKIs used in clinical practice. Some
signaling pathways specific to LSCs have been successfully
identified in CML stem cells. Wnt/b-catenin, Sonic Hedgehog,
Notch and Alox5 signaling pathways play crucial roles in the
maintenance of stem cell functions. The inhibition of these
signaling pathways specifically impairs LSC functions without
affecting normal HSCs. The role of ras signaling pathway in CML
stem cells is poor understood [34].
However, the role of miR-181a in CML has not been well
characterized. In agreement with Ramkissoon et al. [35], our data
revealed that miR-181a was hardly detected in K562 cells using
Northern blot. Our further data showed that overexpression of
miR-181a in K562 cells significantly suppressed cell growth
(Figure 4) and induced G2-phase arrest (Figure 5). Interestingly,
ablation of RalA expression by siRNA also led to almost identical
effects as those produced by miR-181a. Therefore, our results
suggest that miR-181a functions to suppress cell growth by, at least
partially, targeting RalA.
Figure 6. miR-181a promotes apoptosis partially by targeting RalA. K562 cells were transfected with scrambled RNA, miR-181a, or RalA
siRNA and harvested 48 h after transfection. The cells were stained with FITC-conjugated annexin V and PI, followed by flow cytometry analysis.
Annexin V-positive and PI negative cells represent apoptotic cells. *p,0.01, when compared with blank or SCR controls.
doi:10.1371/journal.pone.0032834.g006
miR-181a Downregulates RalA
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32834miR-181 has also been implicated in other leukemias. For
example, Pekarsky et al. showed that miR-181b could inhibit
chronic lymphocytic leukemia (CLL) cells by targeting oncogenic
Tcl1 [18]. Moreover, miR-181 was presumed to be one of the
pathogenic factor of CLL [19]. Recently, another work demon-
strated that miRNA-181 family members were associated with
event-free survival in acute myeloid leukemia (AML) and that
downregulation of the miRNA-181 family contributes to an
aggressive leukemia phenotype through mechanisms associated
with the activation of pathways controlled by toll-like receptors
and interleukin-1b [20].
Inconclusion, ourwork revealed that overexpression of miR-181a
causes cell growth inhibition, G2-phase arrest and apoptosis through
a mechanism that at least partially targets RalA in K562 cells,
suggesting that miR-181a might function as a tumor suppressor in
hematopoietic cells. Our study also indicates that a combination of
computational prediction and expression profiling might be an
applicable choice for the identification of miRNA targets.
Materials and Methods
Cell line
K562 (chronic myelogenous leukemia) cell lines (from the
Institute of Shanghai cell biology, China) were grown in a RPMI-
1640 medium containing 10% fetal calf serum (FCS) at 37uC, in
5% CO2, humidified atmosphere (Thermo FORMA 3110).
miRNA and siRNA transfections
miR-181a duplex (sense: 59-AACAUUCAACGCUGUCGGU-
GAGU-39; antisense: 59-UCACCGACAGCGUU GAAU-
GUUGU-39) and small interfering RNA (siRNA) against RalA
(siRalA) (sense: 59-CGUGGAAACAUCUGCUAAATT-39 and
antisense: 59-UUUAGCAGAU GUUUCCACGTA-39) were syn-
thesized by Shanghai GenePharma Company in China and stored
at 220uC. The miR-181a RNA duplex (mimic) and scramble (Scr)
control miRNA duplex (100 nM) were transfected into K562 cells
using Oligofectamine
TM. Breifly, RNAs were diluted in optiMEM
medium (Invitrogen). The diluted miRNA duplex was then
combined with diluted transfection reagent, followed by incuba-
tion at room temperature for 10 min. The mixture was dispensed
into an empty 24-well plate (Costar). K562 cells were then added
into each well at a concentration of 5610
5 cells per well. Total
RNAs were extracted at 48 h posttransfection for microarray
experiments. Additional transfections were performed to generate
RNA samples for RT-PCR validations.
Computational prediction of miR-181a targets
To identify the miR-181a targets, TargetScan software (version
4.0 July 2007) (7), available at http://genes.mit.edu/targetscan,
was employed. This prediction combines thermodynamics-based
modeling of RNA:RNA duplex interactions with comparative
sequence analysis to predict the miRNA targets conserved across
multiple genomes (Figure 2B). TargetScan requires perfect
complementarity to the seed region of the miRNA, and
subsequently extends these regions to unravel the complementarity
outside the region. This results in filtering of many false-positives
from the beginning of the prediction process. Subsequently, the
predicted binding sites are tested for their thermodynamic
stability. The context score (Table 1) for a specific site is the
sum of the contribution of four features: site-type contribution, 39
pairing contribution, local AU contribution, and position contri-
bution. The sum of the context scores for each miRNA was
calculated, and the most favorable (lowest) was displayed.
Microarray
The total RNA was purified using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions and quantified using
the Agilent 2100 Bioanalyzer with RNA 6000 Nano Reagents and
Supplies (Agilent Technologies, Inc.). The cRNAs were synthe-
sized and labeled with Cy3 and Cy5, respectively. The labeled
cRNA fragments were hybridized with Agilent human 1A 60-mer
oligonucleotide microarray, following Agilent 60-mer oligo
microarray protocol. Hybridized DNA microarrays were scanned
with Agilent 2565BA scanner (Agilent Technologies, Inc.) The raw
intensity profiles were analyzed using Feature Extraction Software,
and p-value LogRatio was used as the criteria to estimate the
differences in gene expression.
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K562 cells transfected with 100 nM of miR-181a RNA duplex
molecule (mimic) or control scrambled miRNA in the presence of
Lipofectamine 2000 reagent for 48 h. Total RNA was extracted in
Trizol (Invitrogen) and quantified by an ultraviolet spectropho-
tometer (UVPupland, USA) at a wavelength of 260 nm. cDNA
was prepared as described above. The levels of miR-181a and U6
small nuclear RNA (snRNA) were determined by the miRNAs
RT-PCR Quantitation Kit (Shang Hai Gene Pharma Company,
China). U6 snRNAs were used as the internal control, and the fold
change for miR-21 expression level was calculated using the
2
2DDCT method.
The RalA mRNAs were determined using SYBR-Green real-
time PCR assay. The PCR primers used were 59-ATCGGAA-
GAAGGTAGTGC-39 and 59-AATCTGCTCC CTGAAGT-39
(RalA); 59-CAACGGATTTGGTCGTATT-39 and 59-CACAG-
TCTTCTGG GTGGC-39 (GAPDH). The levels of RalA mRNA
expression was normalized to that of GAPDH.
Construction of RalA-39-UTR plasmid and reporter assays
Two oligonucleotides, each contains a RalA miR-181a target
site, were synthesized: 59-CCGctcgagATTGCCTACATTTAT-
CATGGTCCTGAATGTAGCGTGTAAATT GCCTACAT-39
(sense strand) and 59-ATAAGAATgcggccgcTTACACGCT
ACATTCAGGACCATGATAAATGTAGGCAATTTACACG-
CTAC-39 (antisense strand). The oligonucleotides were annealed
and amplified by PCR. This PCR product contained two tandem
putative miR-181a binding sites (ctcgagATTGCCTACATTTAT-
CATGGTCCTGAATGTAGCGTGTAAATTGCCTACATTT-
ATCATGGTCCTGAATGTAGCGTGTAAgcggccgc, italics stand
for miR-181a binding sites,underline is the seed sequence of miR-
181a complementary sites) and was cloned into the psiCHECK-2
vector (Promega, Madison, WI) immediately downstream of the
Renilla luciferase reporter gene at XhoI and NotI sites (lower case
letter) to generate psi-CHECK-RALA-UTR [21].
To clone psi-CHECK-RalA-mut-UTR containing mutant




TTACACGCTAC -39) were used. The recognition sequence is
underlined and the seed sequence of miR-181a complementary
sites, TGAATGT, was substituted by TACTAGT.
Cells were cotransfected with miR-181a together with psi-
CHECK-RALA-UTR or psi-CHECK-RALA-mut-UTR and as-
sayed for luciferase activity 24 h posttransfection using Dual-
Luciferase Reporter Assay System (E1910) (Promega). The firefly
luciferase activity was normalized with Renilla luciferase activity
for each sample.
Western blot
Cells were lysed in RIPA buffer in the presence of proteinase
inhibitor (Biocolor BioScience & Technology company, Shanghai,
China). Cell lysates (30 mg) were denatured in Laemmli sample
buffer (Bio-RAD) for 5 min at 95.1uC, electrophoresed on 10%
SDS-PAGE gel, and transferred to a nitrocellulose membrane.
The membrane was blocked with 5% (w/v) fat-free milk in PBS
and 0.5% (v/v) Tween-20 for 1 h. The blots were then incubated
with anti-RalA antibody (Abcam) at room temperature for 2 h.
After washing the blots were then incubated with horseradish
peroxidase-conjugated secondary antibody. The signals were
visualized with enhanced chemiluminescence (ECL) (BeyoECL
Plus, Beyotime company, Haimen, Jiangsu province, China), and
analyzed using BI-2000 system.
Cell growth inhibition
The viability of K562 cells was determined by the 3- (4,5-
dimethylthiazol-2-yl) -2,4-diphenyl-tetrazolium bromide (MTT)
assay. Briefly, cells were seeded at a density of 1610
5 cells/ml in
96-well plates (100 ml/well). The cells were transfected with 181a
mimic, or RalA siRNA or control RNAs at a final concentration of
100 nM using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. A total of 50 ml of transfection
complexes were added directly to the cells.
At 48 h post-transfection, 20 ml of MTT stock solution (5 mg/
ml) was added to each well and the plate was incubated for 4 h at
37uC. The media was then removed and dimethyl sulfoxide
(DMSO) (150 ml) was added to dissolve the blue formazan crystals
produced by live cells from MTT. Cell viability was assessed by
measuring the absorbance at 570 nm on a Bio-Rad microtiter
plate reader. Alternatively, the viable cells were also counted using
trypan blue exclusion assay in triplicate at 24, 48, and 72 h.
Flow cytometry
Cells transfected with 181a mimic and/or siRalA (100 nM)
were fixed with 70% ethanol were stained with propidium iodide
solution (50 mg/ml) containing RNAse A (200 ug/ml). Cell cycle
was analyzed using flow cytometry according to the content of
DNA. For analyzing apoptosis, cells were stained with FITC-
conjugated annexin V and PI. For each sample, data from
approximately 10,000 cells were recorded in the list mode on
logarithmic scales. Apoptotic and necrotic cells were analyzed by
quadrant statistics on propidium iodide (PI)-negative, annexin V-
positive cells and PI/Annexin V double positive cells, respectively.
KEGG analysis
For the RalA pathway analysis, Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway were used to analyze its effector.
KEGG is available at the web (http://www.genome.jp/).The result
was graphed using cytoscape to showthe interactions between RalA
and their potential effectors (http://www.cytoscape.org).
Statistical analysis
All the experiments were carried out in triplicate, and the results
were calculated using SPSS10 software asx6s and statistic analysis
was performed using ANOVA. A value of p,0.05 was considered
to be statistically significant.
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